Peptide Record

Methodology

How this is built, and what it cannot tell you

Every number on this site decomposes into inputs you can check, and every input has a source you can open. Where a figure is a proxy for something we cannot measure, this is where we say so.

Pages

Evidence grading
The five inputs, their thresholds, and how a total becomes a letter.
Extraction
How fields are read from documents, and the current per-field disagreement rates. Read this one.
Collection
Which sources are queried, what rate limits were observed, and what a coverage gap means.
Trending
Why nothing is currently trending, and why that is the correct output.
Vendor transparency
What the score measures, and the thing it cannot tell you.
Submissions
How first-party responses are aggregated, and how adverse reports are routed.
Publication status
What is graded, what is published, and what is still gated.
Corrections and removal
How a voice, vendor, or rights holder gets something changed or taken down.
Vendor right of reply
Contest an input behind a transparency score, with the document that shows it is wrong. Recorded and reviewed, never applied automatically.
Correction or removal of a mention
If a mention attributed to you is wrong, mischaracterises your position, or should come down.

Source tags

Every record carries exactly one

Tags are ordered, and the order is enforced rather than encouraged: nothing below REGULATORY appears above HUMAN-TRIAL on any surface of this site, including search results. The four visual treatments below map to how much a record can be relied on — solid ink for primary evidence, a seal for agency filings, an outline for commentary with no data behind it, and hatched ochre for anything published by someone selling the product.

HUMAN-TRIAL
Peer-reviewed human study.
ANIMAL
Peer-reviewed in vivo animal study.
PRECLINICAL
In vitro, mechanistic or computational work — or, for most records carrying this tag, work whose study design could not be determined. The tag is the floor of the evidence hierarchy, so an unclassified paper cannot outrank a real trial.
REGULATORY
Agency filing, warning letter, alert or adverse event report.
VENDOR-CLAIM
Published by an entity selling the product.
SELF-REVIEWED
Review hosted by the seller being reviewed.
INDEPENDENT-REVIEW
Third-party platform or community review.
EXPERT-COMMENTARY
Podcast, newsletter or clinician commentary. No primary data.
MEDIA
News and trade coverage.
USER-REPORT
First-party submission through our form.

Standing limitations

  • Judgment fields are not human-audited. Study type, sample size, blinding, preregistration, funding, direction of effect, outcome mapping and mention stance are extracted by automated agents. Current disagreement rates.
  • Nothing here verifies what is in a vial. We do not test products. Reviews detect a narrow band of failure and do not detect underdosing, substitution, or degradation, because “no effect” is indistinguishable from a compound that does not work.
  • A grade is not a safety assessment. It measures how much evidence exists for one outcome. A grade A pair can have a serious side-effect profile and a grade E pair can be harmless; neither is what the letter is about.
  • Coverage is incomplete and the gaps are recorded. Where a source blocked us, rate-limited us, or could not supply the window we asked for, the gap is on the peptide record rather than worked around.
  • Mentions are attention, not evidence. They never feed a grade or a transparency score.